---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-26-000023"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:50:34.764739+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Novocure PANOVA-4 trial meets primary endpoint; DCR 74.4% vs 48% historical control in mPDAC

## Summary
- PANOVA-4 met primary endpoint: DCR 74.4% (N=78) vs 48% historical control (N=431), 1-sided p<0.001.
- Secondary endpoints: ORR 34.6% (95% CI 24.2%-46.2%), median OS 9.7 months (95% CI 7.9-12.7 months).
- TTFields therapy with atezolizumab and gem/nab-pac well-tolerated; safety consistent with prior studies.
- Novocure plans to present further PANOVA-4 data at a future scientific forum.

## SEC filing metadata
- accession: 0001645113-26-000023
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000023/0001645113-26-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000023/nvcr-20260326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-26-000023
- JSON: https://secwatch.observer/filing/0001645113-26-000023.json
- Plain text: https://secwatch.observer/filing/0001645113-26-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.